The importance of aeroallergen sensitivity in children with cystic fibrosis
Main Article Content
Keywords
Aspergillus fumigatus, asthma, atopy, children, cystic fibrosis
Abstract
Background: Cystic fibrosis (CF) is an inherited autosomal recessive disorder that causes chronic airway disease. In addition to genetic factors, environmental factors may affect the clinical phenotype of CF. In this study, the presence of aeroallergen sensitivity in our patients with CF and its effects on clinical findings are evaluated.
Methods: In this study, patients included were diagnosed with CF and followed in the Pediatric Respiratory and Allergy Clinic of the Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey. Demographic characteristics, clinical and laboratory findings, skin prick test (SPT) results, and modified Shwachman–Kulczycki (MSK) scores of the patients were evaluated.
Results: We evaluated 51 patients with CF with a median age of 10 (6–18) years. The mean MSK score of the patients was 72.54±11.50, and the mean predictive value of forced expiratory volume (FEV1) in the initial (1st) second was 80.43±19.50. According to SPT, aeroallergen sensitivity was detected in 17 (33.3%) patients. The prevalence of bacterial colonization and bronchiectasis was higher, and MSK scores were lower in Aspergillus fumigatus (AF)-sensitive patients (P ≤ 0.01). However, no similar difference was found in other allergen sensitivities. MSK scores (P = 0.001) and predictive FEV1 values (P = 0.005) of 25 (49%) patients with bacterial colonization were significantly lower than those without colonization.
Conclusion: Aeroallergen sensitivity was detected in approximately one-third of CF patients. Although it has been emphasized in studies that environmental factors may have an impact on lung functions and clinical conditions in CF, the effect of allergens other than AF sensitivity may be less important compared to other environmental factors, such as the presence of bacterial colonization.
References
2. Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semin Immunopathol. 2020;42(1):5–15. 10.1007/s00281-020-00785-1
3. Antunes J, Fernandes A, Miguel Borrego L, Leiria-Pinto P, Cavaco J. Cystic fibrosis, atopy, asthma and ABPA. Allergol Immunopathol. 2010;38:278–84. 10.1016/j.aller.2010.06.002
4. Brand PLP. Bronchodilators in cystic fibrosis. J Soc Med. 2000;93(38):37–9.
5. Janahi IA, Rehman A, Al-Naimi AR. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ann Thorac Med. 2017;12(2):74–82. 10.4103/atm.ATM_231_16
6. Collaco JM, Morrow CB, Green DM, Cutting GR, Mogayzel PJ Jr. Environmental allergies and respiratory morbidities in cystic fibrosis. Pediatr Pulmonol. 2013;48(9):857–64. 10.1002/ppul.22700
7. Warner JO, Kilburn SA. Cystic fibrosis and allergy. Pediatr Allergy Immunol. 1996;7(9):67–9. 10.1111/j.1399-3038.1996.tb00399.x
8. Silverman M, Hobbs FD, Gordon IR, Carswell F. Cystic fibrosis, atopy, and airways lability. Arch Dis Child. 1978;53(11):873–7. 10.1136/adc.53.11.873
9. Moustaki M, Loukou I, Tsabouri S, Douros K. The role of sensitization to allergen in asthma prediction and prevention. Front Pediatr. 2017;5:166. 10.3389/fped.2017.00166
10. Pitcher-Wilmott RW, Levinsky RJ, Gordon I, Turner MW, Matthew DJ. Pseudomonas infection, allergy, and cystic fibrosis. Arch Dis Child. 1982;57(8):582–6. 10.1136/adc.57.8.582
11. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Cystic fibrosis foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):4–14. 10.1016/j.jpeds.2008.05.005
12. Just J, Deslandes-Boutmy E, Amat F, Desseaux K, Nemni A, Bourrat E, et al. Natural history of allergic sensitization in infants with early-onset atopic dermatitis: Results from ORCA Study. Pediatr Allergy Immunol. 2014;25(7):668–73. 10.1111/pai.12287
13. Tu YL, Chang SW, Tsai HJ, Chen LC, Lee WI, Hua MC, et al. PATCH study group. Total serum IgE in a population-based study of Asian children in Taiwan: Reference value and significance in the diagnosis of allergy. PLoS One. 2013;8(11):80996. 10.1371/journal.pone.0080996
14. Doershuk C, Mathews L, Tucker A. A five-year clinical evaluation for a therapeutic program for patients with cystic fibrosis. J Pediatr. 1964;65:677–93. 10.1016/S0022-3476(64)80152-9
15. Alishbayli G, Kilinc AA, Cokugras H. Evaluation of the health-related quality of life in Turkish cystic fibrosis patients. Pediatr Int. 2021;63(8):965–70. 10.1111/ped.14553
16. Wang X, Dockery DW, Wypij D, Gold DR, Speizer FE, Ware JH, et al. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis. 1993;148:1502–8. 10.1164/ajrccm/148.6_Pt_1.1502
17. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159:179–87. 10.1164/ajrccm.159.1.9712108
18. Royal Brompton and Harefield Hospitals Paediatric CF Team. Clinical guidelines: Care of children with cystic fibrosis. 8th ed., 2020. Available from: www.rbht.nhs.uk/childrencf.
19. Green DM, McDougal KE, Blackman SM, Sosnay PR, Henderson LB, Naughton KM, et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res. 2010;11(1):140. 10.1186/1465-9921-11-140
20. Agarwal R, Sehgal IS, Dhooria S, Aggarwal AN. Developments in the diagnosis and treatment of allergic bronchopulmonary aspergillosis. Expert Rev Respir Med. 2016;10(12):1317–34. 10.1080/17476348.2016.1249853
21. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. World Health Organization; GA(2)LEN; allergen. Allergic rhinitis and its impact on asthma (ARIA) 2008 update. Allergy. 2008;63(86):8–160. 10.1111/j.1398-9995.2007.01620.x
22. Weir CB, Jan A. BMI classification percentile and cut off points. 2021, May 9. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2021.
23. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr. 2010;157(5):802–7. 10.1016/j.jpeds.2010.05.018
24. Wilmott RW. The relationship between atopy and cystic fibrosis. Clin Rev Allergy. 1991;9(1–2):29–46. 10.1007/BF02914533
25. Balfour-Lynn IM, Elborn JS. “CF asthma”: What is it and what do we do about it? Thorax. 2002;57(8):742–8. 10.1136/thorax.57.8.742
26. Karaman O, Turgut CS, Uzuner N, Olmez D, Babayigit A, Kose S, et al. The determination of asthma, rhinitis, eczema, and atopy prevalence in 9-to 11-year-old children in the city of Izmir. Allergy Asthma Proc. 2006;27(4):319–24. 10.2500/aap.2006.27.2877
27. Hallstrand TS, Calenoff E, Becker JW, Henderson WR Jr, Aitken ML. The role of allergy in manifestations of respiratory disease in adult cystic fibrosis. Ann Allergy Asthma Immunol. 2004;92:228–33. 10.1016/S1081-1206(10)61552-9
28. Nikolaizik WH, Moser M, Crameri R, Little S, Warner JO, Blaser K, et al. Identification of allergic bronchopulmonary aspergillosis incystic fibrosis patients by recombinant Aspergillus fumigatus I/a-specific serology. Am J Respir Crit Care Med. 1995;152: 634–9. 10.1164/ajrccm.152.2.7633719
29. Kent BD, Lane SJ, van Beek EJ, Dodd JD, Costello RW, Tiddens HA. Asthma and cystic fibrosis: A tangled web. Pediatr Pulmonol. 2014;49(3):205–13. 10.1002/ppul.22934
30. Pabary R. Severe pulmonary exacerbation in cystic fibrosis caused by cat allergy. Paediatr Respir Rev. 2014;15(1):29–31. 10.1016/j.prrv.2014.04.010
31. Sanchez I, Powell RE, Pasterkamp H. Wheezing and air flow obstruction during methacholine challenge in children with cystic fibrosis and in normal children. Am Rev Respir Dis. 1993;147:705–9. 10.1164/ajrccm/147.3.705
32. Koch C, McKenzie SG, Kaplowitz H, Hodson ME, Harms HK, Navarro J, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatr Pulmonol. 1997;24:147–54. 10.1002/(SICI)1099-0496(199708)24:2<147::AID-PPUL15>3.0.CO;2-2
33. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ, et al. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr. 2008;153(6):746–51. 10.1016/j.jpeds.2008.07.010
34. Nikolaizik WH, Schoni MH. Effect of inhaled corticosteroids on lung function of cystic fibrosis patients—a prospective study. Eur Respir J. 1994;7:430S.
35. Levine H, Cohen-Cymberknoh M, Klein N, Hoshen M, Mussaffi H, Stafler P, et al. Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma. J Cyst Fibros. 2016;15(5):652–9. 10.1016/j.jcf.2016.01.003
36. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2012;14(11):CD001915. 10.1002/14651858.CD001915.pub3
37. Calella P, Valerio G, Thomas M, McCabe H, Taylor J, Brodlie M, et al. Association between body composition and pulmonary function in children and young people with cystic fibrosis. Nutrition. 2018;48:73–6. 10.1016/j.nut.2017.10.026
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.